Connective tissue disorders and pregnancy: Recommendations for prescribing

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 43, Issue 4, 1998, Pages 341-349

  Rayburn, William F ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Connective tissue diseases; Lupus erythematosus, systemic; Pregnancy complications; Prescriptions, drug

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; GOLD SALT; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE;

ARTICLE; BREAST FEEDING; CONGENITAL MALFORMATION; CONNECTIVE TISSUE DISEASE; CRANIOFACIAL MALFORMATION; HUMAN; IMMUNE DEFICIENCY; INTRAUTERINE GROWTH RETARDATION; PANCYTOPENIA; PREGNANCY; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENESIS;

ADULT; ANTI-INFLAMMATORY AGENTS; BREAST FEEDING; CONNECTIVE TISSUE DISEASES; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; GUIDELINES; HUMANS; LACTATION; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRESCRIPTIONS, DRUG;

EID: 0031977604     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Noschel H, Peiker G, Muller M, et al: Pharmacokinetics during pregnancy and delivery. Biol Res Pregn 1982;3: 66-73
2. Mirkin BL, Singh S: Placental transfer of pharmacologically active molecules. In Perinatal Pharmacology and Therapeutics. Edited by BL Mirkin. New York, Academic Press, 1976, pp 57-70
3. Livesey G, Rayburn W: Principles of perinatal pharmacology. In Drug Therapy in Obstetrics and Gynecology. Third edition. Edited by WF Rayburn, FP Zuspan. St Louis, Mosby-Year Book, 1992, pp 5-7
4. Fraser F, Sajoo A: Teratogenic potential of cortiocosteroids in humans. Teratology 1995;51:456
5. Reinisch JM, Simon N, Karow W: Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978;202:436-438
6. Scott JR: Fetal growth retardation associated with maternal administration of immunosuppressive drugs. Am J Obstet Gynecol 1977;128:668-676
7. Fine LG, Barnett E, Danovitch G, et al: Systemic lupus erythematosus in pregnancy. Ann Intern Med 1981;94:667-677
8. Fitzsimons R, Greenberger P, Patterson R: Outcome of pregnancy in women requiring corticosteroids for severe asthma. J Allergy Clin Immunol 1986;78:349-353
9. Warrell DW, Taylor R: Outcome for the fetus of mothers receiving prednisolone during pregnancy. Lancet 1968;1: 117-118
10. Brown JH, Maxwell AP, McGeown MG: Outcome of pregnancy following renal transplantation. Ir J Med Sci 1991; 160:255-256
11. Schardein JL: Chemically Induced Birth Defects. Second edition. New York, Marcel Dekker, 1993, p 310
12. Lockshin MD, Druzin M, Qamar T: Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989;160:439-443
13. Cote CJ, Meuwissen H, Pickering R: Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr 1974;85:324-328
14. Cedeqvist LL, Merkatz I, Litwin S: Fetal immunoglobin synthesis following maternal immunosuppression. Am J Obstet Gynecol 1977;129:687-690
15. Ost L, Wettrell G, Bjorkhem I, et al: Prednisolone excretion in human milk. J Pediatr 1985;106:1008-1011
16. Committee on Drugs, American Academy of Pediatrics: The transfer of drugs and other chemicals into human breast milk. Pediatrics 1994;93:137-150
17. Slone D, Heinonen O, Kaufman D: Aspirin and congenital malformations. Lancet 1976;1:1373-1375
18. Lewis RB, Schulman JD: Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labor. Lancet 1973;2:1159-1163
19. Powell JG Jr, Cochrane RL: The effects of a number of nonsteroidal anti-inflammatory compounds on parturition in the rat. Prostaglandins 1982;23:469-488
20. Fuchs F: Prevention of prematurity. Am J Obstet Gynecol 1976;126:809-820
21. Zierler S, Rothman KJ: Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 1985;313:347-352
22. Werler MM, Mitchell A, Shapiro S: The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989;321:1639-1642
23. Levin DL, Fixler D, Morris F, et al: Morphologic analysis of the pulmonary vascular bed in infants exposed in utero to prostaglandin synthetase inhibitors. J Pediatr 1978;92: 478-483
24. Moise KJ, Huhta J, Sharif D, et al: Indomethacin in the treatment of premature labor: Effects on the fetal ductus arteriosus. N Engl J Med 1988;319:327-331
25. Rumack CM, Guggenheim M, Rumack B, et al: Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981;58:52S-56S
26. Corby DG: Aspirin in pregnancy: Maternal and fetal effects. Pediatrics 1978;62:930-945
27. Schiff E, Peleg E, Goldenberg M, et al: The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989;321:351-356
28. Trudinger BJ, Cook C, Thompson R, et al: Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. Am J Obstet Gynecol 1988;159:681-685
29. Beaufils M, Donsimoni R, Uzan S: Prevention of preeclampsia by early antiplatelet therapy. Lancet 1985;1: 840-842
30. Wallenburg HC, Makouitz J, Dekker G: Low-dose aspirin prevents pregnancy-induced hypertension and preeclampsia in angiotensin-sensitive primigravidae. Lancet 1986;1:1-3
31. Benigni A, Gregorini G, Frusen T, et al: Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989;321:357-362
32. Dekker GA, Sibai BM: Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: Rationale, mechanisms and clinical trials. Am J Obstet Gynecol 1993; 168:214-227
33. Hauth JC, Goldenberg RL, Parker R Jr, et al: Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol 1993;168:1083-1093
34. Sibai BM, Caritis SN, Thom E, et al: Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med 1993;329:1213-1218
35. CLASP Collaborative Group: CLASP: A randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women. Lancet 1994; 343:619-625
36. CLASP Collaborative Group: Low dose aspirin in pregnancy and early childhood development: Follow up of the collaborative Low Dose Aspirin Study in Pregnancy. Br J Obstet Gynaecol 1995;102:861-868
37. Silver RK, MacGregor SN, Sholl JS et al: Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993;169:1411-1417
38. Sibai BM, Mirro R, Chesney CM, et al: Low-dose aspirin in pregnancy. Obstet Gynecol 1989;74:551-557
39. Levy G: Salicylate pharmacokinetics in the human neonate. In Basic and Therapeutic Aspects of Perinatal Pharmacology. Edited by PL Morselli, S Garattini, F Sereni. New York, Raven Press, 1975, pp 319-329
40. Findlay JWA, DeAngelis RL, Kearney MF, et al: Analgesic drugs breast milk and plasma. Clin Pharmacol Ther 1981; 29:625-633
41. McNamara PJ, Burgio D, Yoo SD: Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. Toxicol Appl Pharmacol 1991;109:149-160
42. Bennet PN (editor): Drugs and Human Lactation. New York, Elsevier 1988, pp 325-326
43. Adams SS: Absorption, distribution, and toxicity of ibuprofen. Toxicol Appl Pharmacol 1969;15:310-330
44. Ono M: Reproductive studies of ibuprofen by rectum in rats and rabbits. Clin Rep 1984;18:1537-1556
45. Aselton PA, Jick H, Milunsky A, et al: First-trimester drug use and congenital disorders. Obstet Gynecol 1985;65: 451-455
46. Torfs CP, Katz EA, Bateson TF, et al: Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92
47. Momma K, Takeuchi H: Constriction of fetal ductus arteriosus by nonsteroidal antiinflammatory drugs. Adv Prostaglandin Thrombokane Leukotriene 1983;12:499-503
48. Turner GR, Levin DL: Prostaglandin synthesis inhibition in persistent pulmonary hypertension of the newborn. Clin Perinatol 1984;11:581-589
49. Levin DL: Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation. Semin Perinatol 1980;4:35-44
50. Rudolph AM: The effects of nonsteroidal antiinflammatory coumpounds on fetal circulation and pulmonary function. Obstet Gynecol 1981;58:63s-67s
51. Wilkinson AR, Mitchell M, Aynsley-Green A, et al: Persistent pulmonary hypertension and abnormal prostaglandin E levels in preterm infants after maternal treatment with naproxen. Arch Dis Child 1979;54:942-945
52. Wiggins DA, Elliott JP: Oligohydramnios in each sac of a triple gestation caused by Motrin-fulfilling Kock's postulates. Am J Obstet Gynecol 1990;162:460-461
53. Hendricks S, Smith J, Moore D, et al: Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol 1990;97:312-316
54. Townsend RJ, Benedetti T, Erickson S, et al: Excretion of ibuprofen into breast milk. Am J Obstet Gynecol 1984;149: 184-186
55. Weibert RT, Townsend R, Kaiser D, et al: Lack of ibuprofen secretion into human milk. Clin Pharmacol 1982;1:457-459
56. Moise KJ, Ou C, Kirshon B, et al: Placental transfer of indomethacin in the human pregnancy. Am J Obstet Gynecol 1990;162:549-554
57. Katz Z: Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome. Int J Fertil 1984;29:186-188
58. Csaba IF, Sulyok E, Ertl T: Relationship of maternal treatment with indomethacin to persistence of the fetal circulation syndrome. J Pediatr 1978;92:484-489
59. Besinger RE, Niebyl JR, Keyes WG, et al: Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol 1991; 164:981-988
60. Norton ME, Merrill J, Cooper BAB, et al: Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993;329:1602-1607
61. Ajram J, Almirall Pisonero MJ, Valls I: Neonatal morbidity in newborns from mothers treated with indomethacin. J Perinat Med (suppl 1) 1992;20:176-181
62. Rasanen J, Jouppila P: Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: A randomized study. Am J Obstet Gynecol 1995;173:20-25
63. Bivins HA Jr, Newman RB, Fyfe DA, et al: Randomized trial of oral indomethacin and terbutaline for the long-term suppression of preterm labor. Am J Obstet Gynecol 1993;169: 1065-1070
64. Murray HG, Stone PR, Strand L, et al: Fetal pleural effusion following maternal indomethacin therapy. Br J Obstet Gynaecol 1993;100:277-279
65. Moise KJ Jr: Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993;168: 1350-1353
66. Baerts W, Fetter WP, Hop-WC: Cerebral lesions in preterm infants after tocolytic indomethacin Dev Med Child Neurol 1990;32:910-918
67. Herson VC, Krause PJ, Eisenfeld LI, et al: Indomethacin-associated sepsis in very-low-birth-weight infants. Am J Dis Child 1988;142:555-558
68. Major CA, Lewis DF, Harding JA, et al: Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate. Am J Obstet Gynecol 1994;170:102-106
69. Gardner MO, Owen J, Skelly S, et al: Preterm delivery after indomethacin: A risk factor for neonatal complications? J Reprod Med 1996;41:903-906
70. Van der Heijden BJ, Carlus C, Narcy F, et al: Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. Am J Obstet Gynecol 1994;171:617-623
71. Walker MPR, Moore TR, Brace RA: Indomethacin and arginine vasopressin interaction in the fetal kidney: A mechanism of oliguria. Am J Obstet Gynecol 1994;171:1234-1241
72. Itskovitz J, Abramovici H, Brandes J: Oligohydramnion, meconium and perinatal death concurrent with indomethacin treatment in human pregnancy. J Reprod Med 1980;24:137-140
73. Schoenfeld A, Freedman S, Hod M, et al: Antagonism of antihypertensive drug therapy in pregnancy by indomethacin? Am J Obstet Gynecol 1989;161:1204-1205
74. Sorensen TK, Eastering TR, Carlson KL, et al: The maternal hemodynamic effect of indomethacin in normal pregnancy. Obstet Gynecol 1992;79:661-663
75. Mousavy SM: Indomethacin induces hypertensive crisis in preeclampsia irrespective of prior antihypertensive drug therapy (lett). Am J Obstet Gynecol 1991;165:1577
76. Eeg-Olofsson O, Malmros I, Elwin CE, et al: Convulsions in a breast-fed infant after maternal indomethacin. Lancet 1978;2:215
77. Suhonen R: Hydroxychloroquine administration in pregnancy. Arch Dermatol 1983;119:185-186
78. Smith DW: Dysmorphology (teratology). J Pediatr 1966;69: 1150-1169
79. Parke AL: Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1988;15:607-610
80. Levy M, Buskila D, Gladman DD, et al: Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991;8:174-178
81. Parke A, West B: Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996;23: 1715-1718
82. Buchanan NM, Toubi E, Khamashta MA, et al: Hydroxychloroquine and lupus pregnancy: Review of series of 36 cases. Ann Rheum Dis 1996;55:486-488
83. Wolfe MS, Cordero JF: Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J 1985;290: 1466-1467
84. Nation RL, Hackett L, Dusci E, Ilett K: Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol 1984;17: 368-369
85. Rocker I, Henderson WJ: Transfer of gold from mother to fetus. Lancet 1976;1:1216-1217
86. Cohen DL, Orzel J, Taylor A: Infants of mothers receiving gold therapy (lett). Arthritis Rheum 1981;24:104-105
87. Tarp U, Graudal H: A follow-up study of children exposed to gold compunds in utero. Arthritis Rheum 1985;28: 235-236
88. Miyamoto T, Miyajl S, Horiuchi Y: Gold therapy in bronchial asthma: Special emphasis upon blood levels of gold and its teratogenicity. J Jpn Soc Intern Med 1974; 63:1190-1197
89. Needs CJ, Brooks PM: Antirheumatic medication in pregnancy. Br J Rheumatol 1985;24:282-290
90. Blau SP: Metabolism of gold during lactation. Arthritis Rheum 1973;16:777-778
91. Rooney TW, Lorber A, Veng-Pedersen P, et al: Gold pharmacokinetics in breast mild and serum of a lactating woman. J Rheumatol 1987;14:1120-1122
92. Ostensen M, Skavdal K, Myklebust G, et al: Excretion of gold into human breast mild. Eur J Clin Pharmacol 1986; 31:251-252
93. Bennett PN, Humphries SJ, Osborne JP, et al: Use of sodium aurothiomalate during lactation. Br J Clin Pharmacol 1990; 29:777-779
94. Beckman DA, Brent RL: Mechanisms of teratogenesis. Annu Rev Pharmacol Toxicol 1984;24:483-500
95. Wilson JG, Scott W, Ritter E, et al: Comparative distribution and embryotoxicity of methotrexate in pregnant rats and Rhesus monkeys. Teratology 1979;19:71-80
96. Ichinoe K, Wake N, Shinkai N, et al: Nonsurgical therapy to preserve oviduct function in patients with tubal pregnancies. Am J Obstet Gynecol 1987;156:484-487
97. Patsner B, Kenigsberg D: Successful treatment of persistent ectopic pregnancy with oral methotrexate therapy. Fertil Steril 1988;50:982-983
98. Feldkamp M, Carey JC: Clinical teratology counseling and consultation case report: Low dose methotrexate exposure in the early weeks of pregnancy. Teratology 1993;47: 533-539
99. Hausknecht RU: Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995;333:537-540
100. Schardein JL: Chemically Induced Birth Defects. Second edition. New York, Marcel Dekker, 1993, pp 474-478
101. Peterson AR: Oncogenic transformation of C3H/10T1/2C1 8 mouse embryo fibroblasts by inhibitors of nuclectide metabolism. Basic Life Sci 1985;31:465-479
102. Schmid B: Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptipurine, methotrexate or cyclosporin A. Toxicology 1984;31:9-21
103. Johns D, Rotherford L, Leighton P, et al: Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972; 112:978-980
104. Greenberg LH, Tanaka KR: Congenital anomalies probably induced by cyclophosphamide. JAMA 1964;188:423-426
105. Coates A: Cyclophosphamide in pregnancy. Aust NZ J Obstet Gynaecaol 1970;10:33-34
106. Toledo TM, Harper R, Moser R: Fetal effects during cyclophosphamide and irradiation therapy. Ann Intern Med 1971;74:87-91
107. Murray CL, Reichert M, Anderson J: Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. JAMA 1984;252:2607-2613
108. Kirshon B, Wasserstram N, Willis R, et al: Teratogenic effects of first trimester cyclophosphamide therapy. Obstet Gynecol 1988;72:462-467
109. Zemlickis D, Lishner M, Erlich R, et al: Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 1993;13:139-143
110. Mutchinick O, Aizpuru E, Grether P: The human teratogenic effect of cyclophosphamide. Teratology 1992;45: 329
111. Pizzuto J, Aviles A, Norrega L, et al: Treatment of acute leukemia during pregnancy: Presentation of nine cases. Cancer Treat Rep 1980;64:679-683
112. Nicholson HO: Cytotoxic drugs in pregnancy: Review of reported cases. J Obstet Gynaecol Br Commonw 1968;75: 307-312
113. Wiernik PH, Duncan JH: Cyclophosphamide in human milk. Lancet 1971;1:912
114. Durodola JI: Administration of cyclophosphamide during late pregnancy and early lactation: A case report. J Natl Med Assoc 1979;71:165-166
115. Voogd CD: Azathioprine, a genotoxic agent to be considered non-genotoxic in man. Mutat Res 1989;221:133-152
116. Golby M: Fertility after transplantation. Transplantation 1970;10:201-212
117. Haagsma EB, Visser G, Klompmaker I, et al: Successful pregnancy after orthotopic transplantation. Obstet Gynecol 1989;74:442-443
118. Baxi LV, Rho RB: Pregnancy after cardiac transplantation. Am J Obstet Gynecol 1993;169:33-34
119. Pirson Y, VanLierde M, Ghgsen J, et al: Retardation of fetal growth in patients receiving immunosuppressive therapy (lett). N Engl J Med 1985;313:328
120. Coulam CB, Moyer TP, Jiang NS, et al: Breast-feeding after renal transplantation. Transplant Proc 1982;14:605-609
121. Grekas DM, Vasiliou SS, Lazarids AN: Immunosuppressive therapy and breast-feeding after renal transplantation. Nephron 1984;37:68